Sandra Gollnick

Professor
Department of Immunology
Roswell Park Cancer Institute
United States of America

Professor Oncology
Biography

Dr. Gollnick joined the faculty at RPCI in 1990 after postdoctoral training at DNAX Research Institute in Palo Alto, CA and serving as a staff scientist at ImmunLogic Pharmaceutical Corp.  Dr. Gollnick has been funded by the National Cancer Institute for the past 17 years and is currently the PI as well as a Project Leader of a Program Project Grant continuously funded for the past 21 years. Dr. Gollnick is an Associate Editor of Photochemistry and Photobiology and has served as a reviewer for numerous journals including Cancer Research, Journal of Immunology and Oncogene. Dr. Gollnick is also a member of the NCI Radiation Therapeutics and Biology Study Section and has reviewed grants for the US Army Research Program as well as the Canadian and Dutch Cancer Societies. Dr. Gollnick served as Director of Graduate Studies for the Tumor Immunology Program for many years and is currently a member of the Graduate Studies Steering Committee. She was honored with the Excellence in Graduate Education Award in 2010.

Research Intrest

The use of photodynamic therapy, in both pre-clinical and clinical settings as a means of enhancing anti-tumor immunity through alteration of tumor microenvironments

List of Publications
Riddell JR, Maier P, Sass SN, Moser MT, Gollnick SO, et al. (2012) Peroxiredoxin 1 stimulates endothelial cell expression of VEGF via TLR4 dependent activation of HIF-1α. PLoS One 7: e50394
Riddell JR, Bshara W, Moser MT, Spernyak JA, Gollnick SO, et al. (2011) Peroxiredoxin 1 controls prostate cancer growth through Toll-like receptor 4 dependent regulation of tumor vasculature. Cancer Res 71: 1637-1646
Kabingu E, Oseroff AR, Wilding GE, Gollnick SO, (2009) Enhanced systemic immune reactivity to a basal cell carcinoma associated antigen following photodynamic therapy. Clin. Cancer Res 15: 4460-4466